Business Context and Reporting Period
Company: Sunshine Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 25, 2022
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $19.5 million.
- Securities Issued:
- 2,472,820 shares of common stock.
- 2,390,025 Pre-Funded Warrants (exercisable for one share each at $0.001).
- Investor Warrants to purchase up to 9,725,690 shares of common stock.
- Offering Prices:
- Common Stock + 2 Investor Warrants: $4.01 per unit.
- Pre-Funded Warrant + 2 Investor Warrants: $4.009 per unit.
- Investor Warrant Terms: Exercise price of $3.76 per share; exercisable immediately; expire five years from issuance.
- Transaction Costs: Placement agent (Aegis Capital Corp.) received a 10% commission, a 2% non-accountable expense allowance, and will receive 5% of proceeds from any future exercise of Investor Warrants.
Note: The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes and Closing
The private placement closed on April 28, 2022. The transaction represents a significant increase in the company's capital base through the issuance of new equity and warrant instruments. The company relied on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D for the unregistered sale of these securities.
Guidance, Risks, and Contingencies
- Registration Rights Obligation: The Company must file a resale registration statement with the SEC within 15 days of the closing date (by May 13, 2022).
- Effectiveness Deadline: The Registration Statement must be declared effective within 15 days of filing, or 45 days if reviewed by the SEC.
- Liquidated Damages: The Company is obligated to pay liquidated damages to investors if it fails to file the registration statement on time, fails to have it declared effective within the required timeframe, or fails to maintain its effectiveness.
- Future Dilution: The issuance of Pre-Funded Warrants and Investor Warrants creates potential for future dilution upon exercise.
Investor Verification Checklist
- Verify the effective date of the resale registration statement filed by the Company to ensure compliance with the 15-day/45-day deadlines.
- Confirm the exact net proceeds after deducting the 12% upfront transaction costs (10% commission + 2% expense allowance) and any other transaction-related expenses.
- Review the full text of the Securities Purchase Agreement and Warrant forms (Exhibits 10.2, 10.3, 10.5) for specific anti-dilution provisions and adjustment mechanisms.
- Monitor future filings for the exercise of Pre-Funded Warrants, which are immediately exercisable at a nominal price.